| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,864 | 0,869 | 13:03 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SYNTHAVERSE Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 47,800 | -0,42 % | Novonesis (Novozymes A/S): Novonesis issues EUR 1.7 billion senior unsecured notes | On March 12, 2026, Novonesis, through Novozymes A/S, successfully priced and closed an aggregate principal amount of EUR 1.7 billion senior unsecured notes (the "Notes"). The issuance was completed... ► Artikel lesen | |
| GENMAB | 236,20 | +2,12 % | NICE says no to Genmab cervical cancer therapy | ||
| ARBUTUS BIOPHARMA | 3,744 | +0,70 % | ARBUTUS BIOPHARMA CORPORATION im Bewertungsfokus | ||
| VERICEL | 27,600 | -1,43 % | Leerink reiterates Outperform on Vericel stock, $46 target | ||
| MOLECULIN BIOTECH | 2,010 | -0,50 % | Moleculin Biotech: CEO gibt Update zu entscheidender Leukämie-Studie | ||
| MUSTGROW BIOLOGICS | 0,310 | 0,00 % | Sektor-Rotation spricht für BioTech und LifeSciences! BASF, MustGrow, Novo Nordisk und BioNTech auf der Startrampe | Überraschungen sind derzeit breit gestreut. Der ehemalige Landwirtschaftsminister Cem Özdemir wird nun den Landtag in Baden-Württemberg anführen. Die Grünen holten in einem Sturmlauf über 30 % der Stimmen... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 31,500 | +1,51 % | Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed | WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,290 | -1,53 % | BioXcel Therapeutics schließt registrierte Direktplatzierung über 8 Mio. US-Dollar ab | ||
| REGENXBIO | 7,200 | -4,00 % | REGENXBIO Inc.: Regenxbio Reports New Positive Interim Data From Phase I/ii Affinity Duchenne Trial Of Rgx-202 | Investigational RGX-202 continues to demonstrate evidence of positively changing disease trajectory for Duchenne
Pivotal dose participants exceeded external controls across... ► Artikel lesen | |
| AKEBIA | 1,224 | -4,00 % | Akebia auf Leerink-Konferenz: Strategischer Fokus auf Vafseo und die Produktpipeline | ||
| ZEVRA THERAPEUTICS | 8,750 | 0,00 % | Zevra Therapeutics: Zevra Reports Fourth Quarter and Full Year 2025 Financial Results | Q4 net revenue of $34.1 million, representing 31% growth quarter-over-quarter FY 2025 net revenue of $106.5 million- driven by growth in MIPLYFFA net revenue to $87.4 million 2025 EPS of $1.40 basic... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 6,300 | -0,79 % | Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors | - City of Hope to Evaluate PEDMARK- for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors - - Initiation of Study Reflects Growing Clinical Interest in Addressing... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 14,640 | +9,09 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results | Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiated... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 6,550 | 0,00 % | BTIG reiterates Buy on Cartesian Therapeutics stock, $44 target | ||
| NANOBIOTIX | 29,150 | +1,04 % | Nanobiotix S.A. - 6-K, Report of foreign issuer |